Getting a second opinion before you travel

Choose a clinician with relevant expertise in your condition and no financial relationship to the proposed provider, manufacturer or referral service. Declare any unavoidable conflict. Send the diagnosis, current records, proposed product, cell source, processing, dose, route, indication, quote, consent and regulatory explanation. A brand name alone is insufficient. Ask whether the diagnosis is secure and whether further examination or testing is needed. A remote file review may identify gaps but cannot replace every clinical assessment. Request a comparison with established care, including the consequences of delay or no treatment. The reviewer should identify which options are guideline-supported and which are research. Ask whether the proposed evidence matches the same product and population. Mechanistic papers and studies of a different tissue source should be labelled as indirect. Verify the legal route separately with the competent authority. A clinician's opinion about potential benefit cannot authorise a product or trial. For a trial, match the sponsor, site, protocol, EU trial number, recruitment status and intervention in CTIS. Ask the reviewer to read the official record, not only the clinic summary. Discuss material risks from both the product and administration route, along with patient-specific contraindications. No single phrase such as autologous or GMP removes that analysis. Ask what outcome would be meaningful, how it should be measured and when. Avoid a decision based on an undefined chance of improvement. Review the full financial exposure and who pays for complications. The clinician may not provide financial advice, but should know when cost pressure is distorting consent. Document the second opinion and the evidence reviewed. A short verbal reassurance is difficult to use for later care or to reconcile conflicting recommendations. If opinions differ, ask each clinician to state the factual or value assumption behind the difference. A multidisciplinary review may be useful when several specialties are involved. Do not let the provider select the only reviewer. A paid referral network or testimonial contact is not independent simply because it is outside the facility. A provider that discourages scrutiny, imposes a same-day deadline or refuses to release documents creates a consent red flag. Pause the process. The purpose is not to eliminate all uncertainty. It is to identify unsupported assumptions, time-sensitive alternatives and the conditions under which participation might be reasonable. Keep the final decision separate from the second opinion. The patient may decline even when research is lawful, and may be ineligible even when willing to accept uncertainty.

Sources & further reading

• Stem-cell trials registry (ClinicalTrials.gov) ↗
• Peer-reviewed research (PubMed) ↗
• ISSCR — patient resources ↗
• FDA — consumer guidance ↗
• EMA — ATMP framework ↗

Educational guide; most uses are investigational. Verify the exact product, indication and provider with current regulator records and an independent qualified physician.